EFFICACY OF FDA-APPROVED DISEASE-MODIFYING THERAPIES (DMTS) VERSUS ACTIVE COMPARATOR MEDICATIONS FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS: A SYSTEMATIC REVIEW

被引：0
|
作者：
Lingohr-Smith, M. [1 ]
Deitelzweig, C. [2 ]
Lin, G. [3 ]
Lin, J. [4 ]
机构：
[1] Novosys Hlth, Basking Ridge, NJ USA
[2] Novosys Hlth, Green Brook, NJ USA
[3] Novosys Hlth, Morris Plains, NJ USA
[4] Novosys Hlth, Martinsville, NJ USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO106
引用
收藏
页码：S324 / S324
页数：1
相关论文
共 50 条
  • [31] Impact of disease-modifying therapies on MRI outcomes in patients with relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis
    Bose, Debdipta
    Ravi, Renju
    Maurya, Miteshkumar
    Pushparajan, Libby
    Konwar, Mahanjit
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 61
  • [32] Disease-modifying treatments for multiple sclerosis - a review of approved medications
    Torkildsen, O.
    Myhr, K. -M.
    Bo, L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 18 - 27
  • [33] Highly active disease and access to disease-modifying treatments in patients with relapsing-remitting multiple sclerosis in Poland
    Brola, Waldemar
    Adamczyk-Sowa, Monika
    Kulakowska, Alina
    Glazewska, Joanna
    Smaga, Anna
    Bartosik-Psujek, Halina
    NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2022, 56 (03) : 256 - 260
  • [34] Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis
    Zimmermann, Marita
    Brouwer, Elizabeth
    Tice, Jeffrey A.
    Seidner, Matt
    Loos, Anne M.
    Liu, Shanshan
    Chapman, Richard H.
    Kumar, Varun
    Carlson, Josh J.
    CNS DRUGS, 2018, 32 (12) : 1145 - 1157
  • [35] ESTIMATING THE FISCAL CONSEQUENCES OF INVESTMENTS IN DISEASE-MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY
    Mennini, F. S.
    Kotsopoulos, N.
    Connolly, M.
    Gianinazzi, M.
    Pellirone, M.
    Marcellusi, A.
    VALUE IN HEALTH, 2020, 23 : S627 - S628
  • [36] Safety outcomes of disease-modifying therapies for relapsing-remitting multiple sclerosis: A network meta-analysis
    Lucchetta, Rosa C.
    Leonart, Leticia P.
    Becker, Jefferson
    Pontarolo, Roberto
    Fernandez-Llimos, Fernando
    Wiens, Astrid
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 35 : 7 - 15
  • [37] Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study)
    Fernandez, Oscar
    Duran, Eduardo
    Ayuso, Teresa
    Hernandez, Luis
    Bonaventura, Inmaculada
    Forner, Mireia
    PLOS ONE, 2017, 12 (10):
  • [38] Using number needed to treat to compare the efficacies of disease-modifying therapies in relapsing-remitting multiple sclerosis
    Mikol, D.
    Bennett, R.
    Divan, V.
    Hughes, B.
    AL-Sabbagh, A.
    JOURNAL OF NEUROLOGY, 2007, 254 : 136 - 136
  • [39] Trends in disease-modifying therapies' (DMTs) use and efficacy between 2010 and 2017 in outpatients with relapsing-remitting-multiple-sclerosis (RRMS) in Germany
    Bergmann, A.
    Braune, S.
    Dikow, H.
    Rossnagel, F.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 571 - 572
  • [40] New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come
    Nicholas, J.
    Morgan-Followell, B.
    Pitt, D.
    Racke, M. K.
    Boster, A.
    JOURNAL OF CENTRAL NERVOUS SYSTEM DISEASE, 2012, 4 : 81 - 103
12345